- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01081834
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
February 15, 2017 updated by: Janssen Research & Development, LLC
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus (T2DM).
This is a randomized (study drug assigned by chance), double blind (neither the patient or the study doctor will know the name of the assigned treatment), parallel-group, 3 arm (patients will be assigned to 1 of 3 treatment groups) multicenter study to determine the efficacy, safety, and tolerability of canagliflozin (100 mg and 300 mg) compared to placebo (a capsule that looks like all the other treatments but has no real medicine) in patients diagnosed with T2DM who are not achieving an adequate response from diet and exercise to control their diabetes.
Approximately 450 patients with inadequate glycemic control with diet and exercise will receive once-daily treatment with canagliflozin 100 mg or 300 mg once daily for 52 weeks or 26 weeks of double-blind treatment with placebo followed by 26 weeks of sitagliptin 100 mg (sitagliptin is an antihyperglycemic agent that will allow patients randomized to the placebo group to improve glycemic control and remain in the study).
Patients will participate in the study for approximately 60 to 68 weeks (referred to as the Main Study).
The study will also include a High Glycemic Substudy in 50 to 100 patients with T2DM who have poorer glycemic control with diet and exercise.
Patients in the substudy will be assigned to receive double-blind canagliflozin 100 mg or 300 mg for 26 weeks and the total duration of patient participatation in the substudy will be approximately 34 to 42 weeks.
During treatment, if a patient's fasting blood sugar remains high despite treatment with study drug and reinforcement with diet and exercise, the patient will receive treatment with metformin (rescue therapy) consistent with local prescribing information.
Study drug will be taken orally (by mouth) once daily before the first meal each day unless otherwise specified.
Patients will take single blind placebo for 1 or 2 weeks (wks) before randomization to the Main Study or the High Glycemic Substudy.
Study Type
Interventional
Enrollment (Actual)
678
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Horn, Austria
-
Salzburg, Austria
-
Wien, Austria
-
-
-
-
-
Barranquilla, Colombia
-
Bogota, Colombia
-
-
-
-
-
Pärnu, Estonia
-
Tartu, Estonia
-
Viljandi, Estonia
-
-
-
-
-
Guatemala, Guatemala
-
-
-
-
-
Reykjavik, Iceland
-
-
-
-
-
Bangalore, India
-
Hyderabad, India
-
Nagpur, India
-
-
-
-
-
Busan, Korea, Republic of
-
Goyang-Si, Korea, Republic of
-
Jeonju-Si, Korea, Republic of
-
Seoul, Korea, Republic of
-
Wonju-Si, Korea, Republic of
-
-
-
-
-
Kaunas, Lithuania
-
Klaipeda, Lithuania
-
Siauliai, Lithuania
-
Vilnius, Lithuania
-
Vilnius Lt, Lithuania
-
-
-
-
-
Kelantan, Malaysia
-
Kuala Lumpur, Malaysia
-
Kuala Lumpur N/A, Malaysia
-
-
-
-
-
Aguascalientes, Mexico
-
Guadalajara, Mexico
-
Mex, Mexico
-
Monterrey, Mexico
-
Zapopan, Mexico
-
-
-
-
-
Makati, Philippines
-
Manila, Philippines
-
Marikina City, Philippines
-
Pasay, Philippines
-
-
-
-
-
Katowice, Poland
-
Torun, Poland
-
Warszawa, Poland
-
-
-
-
-
Fajardo, Puerto Rico
-
Ponce, Puerto Rico
-
San Juan, Puerto Rico
-
-
-
-
-
Baia Mare, Romania
-
Brasov, Romania
-
Bucharest, Romania
-
Targu Mures, Romania
-
-
-
-
-
Halfway, South Africa
-
Pretoria, South Africa
-
-
-
-
-
Alcala De Henares, Spain
-
Elche, Spain
-
Girona, Spain
-
Pozuelo De Alarcon, Spain
-
-
-
-
-
Göteborg, Sweden
-
Lund, Sweden
-
Malmö, Sweden
-
Skene, Sweden
-
-
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
California
-
Concord, California, United States
-
Greenbrae, California, United States
-
Los Angeles, California, United States
-
Spring Valley, California, United States
-
-
Colorado
-
Colorado Springs, Colorado, United States
-
Denver, Colorado, United States
-
Northglenn, Colorado, United States
-
-
Illinois
-
Springfield, Illinois, United States
-
-
Indiana
-
Evansville, Indiana, United States
-
-
Louisiana
-
Baton Rouge, Louisiana, United States
-
Metairie, Louisiana, United States
-
-
New Jersey
-
Meridian, New Jersey, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
New York, New York, United States
-
West Seneca, New York, United States
-
-
North Carolina
-
Mooresville, North Carolina, United States
-
-
Pennsylvania
-
Perryopolis, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
-
South Carolina
-
Taylors, South Carolina, United States
-
-
Texas
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
San Antonio, Texas, United States
-
-
Virginia
-
Norfolk, Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All patients must have a diagnosis of T2DM
- Patients in the main study must have a Hemoglobin A1c (HbA1c) between >=7% and <=10% and a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)
- Patients in the High Glycemic Cohort Substudy must have an HbA1c between >10% and <=12% and a FPG <=350 mg/dL (19.44 mmol/L)
Exclusion Criteria:
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Canagliflozin 100 mg
Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
|
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
|
Experimental: Canagliflozin 300 mg
Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
|
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
|
Experimental: Placebo/Sitagliptin
In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
|
One matching placebo capsule orally once daily for 26 weeks (Main Study)
One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With HbA1c <7% at Week 26 (Main Study)
Time Frame: Week 26
|
The table below shows the percentage of patients with HbA1c <7% at Week 26.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.
|
Week 26
|
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Body Weight From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
|
Day 1 (Baseline) and Week 26
|
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Triglycerides From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
|
Day 1 (Baseline) and Week 26
|
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
|
Day 1 (Baseline) and Week 26
|
Percentage of Patients With HbA1c <7% at Week 26 (High Glycemic Substudy)
Time Frame: Week 26
|
The table below shows the percentage of patients with HbA1c <7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Week 26
|
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)
Time Frame: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7.
- Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0.
- Gilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther. 2017 Apr;8(2):451-458. doi: 10.1007/s13300-017-0232-0. Epub 2017 Feb 14.
- Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4.
- John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868.
- Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
- Blonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28.
- Gavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693-702. doi: 10.1185/03007995.2015.1067192. Epub 2015 Sep 4.
- Cefalu WT, Stenlof K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27.
- Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82. doi: 10.1111/jch.12425. Epub 2014 Oct 20.
- Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014 May;126(3):16-34. doi: 10.3810/pgm.2014.05.2753.
- Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
- Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A, Shaw W, Usiskin K, Desai M, Meininger G. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014 Apr 18;14:37. doi: 10.1186/1472-6823-14-37.
- Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
- Lavalle-Gonzalez FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14.
- Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014 May;57(5):891-901. doi: 10.1007/s00125-014-3196-x. Epub 2014 Mar 1.
- Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014 Feb;30(2):163-75. doi: 10.1185/03007995.2013.850066. Epub 2013 Oct 28.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
March 4, 2010
First Submitted That Met QC Criteria
March 4, 2010
First Posted (Estimate)
March 5, 2010
Study Record Updates
Last Update Posted (Actual)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 15, 2017
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Sodium-Glucose Transporter 2 Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
- Canagliflozin
Other Study ID Numbers
- CR017011
- 28431754DIA3005 (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Canagliflozin
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type 2United States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Research & Development, LLCCompletedDiabetes Mellitus, Type 2United States, Brazil
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type 2United States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCThe George Institute for Global Health, AustraliaCompletedDiabetes Mellitus, Type 2 | AlbuminuriaAustralia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
-
Janssen Research & Development, LLCCompletedDiabetes Mellitus, Type 1United States, Canada